Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics Inc. (DE:1S90)
:1S90
Total Valuation
Seres Therapeutics has a market cap or net worth of €130.40M. The enterprise value is €206.38M.
Market Cap€130.40M
Enterprise Value€206.38M
Share Statistics
Seres Therapeutics has 9,046,519 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding9,046,519
Owned by Insiders2.45%
Owned by Institutions0.14%
Financial Efficiency
Seres Therapeutics’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is -104.64%.
Return on Equity (ROE)<0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)-104.64%
Return on Capital Employed (ROCE)-1.23
Revenue Per Employee0.00
Profits Per Employee1.32K
Employee Count103
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Seres Therapeutics is ―. Seres Therapeutics’s PEG ratio is -189.72.
PE Ratio―
PS Ratio0.00
PB Ratio187.37
Price to Fair Value187.37
Price to FCF-17.34
Price to Operating Cash Flow-8.22
PEG Ratio-189.72
Income Statement
In the last 12 months, Seres Therapeutics had revenue of 0.00 and earned 136.00K in profits. Earnings per share was -18.86.
Revenue0.00
Gross Profit-3.53M
Operating Income-121.31M
Pretax Income-125.77M
Net Income136.00K
EBITDA-120.30M
Earnings Per Share (EPS)-18.86
Cash Flow
In the last 12 months, operating cash flow was -23.05M and capital expenditures -313.00K, giving a free cash flow of -23.37M billion.
Operating Cash Flow-23.05M
Free Cash Flow-23.37M
Free Cash Flow per Share-2.58
Dividends & Yields
Seres Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-4.12
52-Week Price Change-23.67%
50-Day Moving Average14.88
200-Day Moving Average9.81
Relative Strength Index (RSI)48.38
Average Volume (3m)93.00
Important Dates
Seres Therapeutics upcoming earnings date is Mar 10, 2026, Before Open (Confirmed).
Last Earnings DateNov 5, 2025
Next Earnings DateMar 10, 2026
Ex-Dividend Date―
Financial Position
Seres Therapeutics as a current ratio of 0.94, with Debt / Equity ratio of 195.10%
Current Ratio0.94
Quick Ratio0.94
Debt to Market Cap0.04
Net Debt to EBITDA-0.55
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Seres Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Seres Therapeutics EV to EBITDA ratio is -23.80, with an EV/FCF ratio of -17.74.
EV to Sales0.00
EV to EBITDA-23.80
EV to Free Cash Flow-17.74
EV to Operating Cash Flow-17.79
Balance Sheet
Seres Therapeutics has €47.64M in cash and marketable securities with €85.25M in debt, giving a net cash position of -€37.62M billion.
Cash & Marketable Securities€47.64M
Total Debt€85.25M
Net Cash-€37.62M
Net Cash Per Share-€4.16
Tangible Book Value Per Share€0.09
Margins
Gross margin is -25.47%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-25.47%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Seres Therapeutics is €18.73, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€18.73
Price Target Upside16.61% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―